Metabolism

Two Understudied PFAS Linked to Higher Liver Cancer Risk

A USC study finds that elevated blood levels of PFHpA and PFNA double liver cancer odds, particularly in people genetically susceptible to fatty liver disease.

Published November 19, 2026 Read 3 min 471 words Topic Metabolism
Reviewed by: Dr. Michael Teplitsky, MD · November 2026

Study Links Two Newer Forever Chemicals to Liver Cancer

Two understudied per- and polyfluoroalkyl substances (PFAS) compounds are associated with a two to 2.5-fold increase in the odds of developing liver cancer. Researchers at the Keck School of Medicine of the University of Southern California (USC) published the findings in Environmental Health Perspectives after evaluating 12 distinct PFAS chemicals.

The analysis identified significant associations for two specific compounds: PFHpA and PFNA. PFHpA was introduced as an alternative to legacy chemicals like perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) after manufacturers phased them out due to health concerns.

PFAS persist for years in the human body and drinking water systems. Hepatocellular carcinoma (HCC) is the primary form of liver cancer and carries a five-year survival rate below 20 percent.

Blood Samples Drawn Years Before Cancer Diagnosis

Researchers evaluated blood samples collected an average of 7.8 years before cancer diagnosis to assess chemical exposure before clinical disease appeared. The nested case-control design matched 223 participants who eventually developed HCC with 223 disease-free controls.

All participants came from the Multiethnic Cohort (MEC) study, which has followed more than 215,000 residents across California and Hawaii since the 1990s. Comparing exposure brackets showed that participants in the highest quartile of PFHpA or PFNA had 2 to 2.5 times higher odds of liver cancer than those in the lowest quartile.

The finding for PFHpA independently aligns with a National Cancer Institute (NCI) study published two months earlier that also identified an association with liver cancer risk.

Genetic Susceptibility to Fatty Liver Multiplies Risk

Genetic predisposition to metabolic dysfunction-associated steatotic liver disease (MASLD) substantially amplifies the link between PFHpA exposure and liver cancer. Investigators calculated a polygenic risk score for fatty liver disease across all 446 participants to evaluate this gene-environment interaction.

Participants with high genetic susceptibility for MASLD showed the strongest link between PFHpA exposure and liver cancer development. Among participants with low genetic susceptibility to fatty liver disease, researchers observed no statistically significant association between PFHpA and HCC.

MASLD is the fastest-growing contributor to primary liver cancer cases. Mechanistic data suggest PFAS disrupt hepatic lipid metabolism, promoting the accumulation of fat that can advance to cellular damage over time.

Context and Practical Limits of the Research

Observational cohort data establish a statistical correlation between chemical exposure and cancer risk, but they do not prove direct causation. The study drew on a single baseline blood measurement for each participant, which cannot track fluctuations in individual exposure over several decades.

The findings evaluate 223 cancer cases within a specific multiethnic cohort and require further replication across varied geographic populations. In addition, the study did not test specific clinical interventions to alter chemical clearance rates.

Individuals managing metabolic dysfunction or elevated liver enzymes can discuss comprehensive hepatic screening and metabolic risk factors with their clinician.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
Primary source: View original source — referenced for fact-checking; this analysis is independent editorial content.
Found this useful?

Related Articles

Want a clinician to work up your metabolic numbers?

Opt Health runs fasting insulin, A1C, a full lipid panel and 50+ other markers, then builds a treatment plan — GLP-1s included where they're appropriate — with a physician who reviews the data with you directly.

See Opt Health's metabolic program →

Topic updates

Get the weekly metabolic health roundup

Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.

No spam. Unsubscribe anytime.

Understand Your Health Better

Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results